Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 56 articles: HTML format

Single Articles

March 2026
1. NALINI M, O'Brien KM, Calafat AM, Wang L, et al
   Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.
   J Natl Cancer Inst. 2026 Mar 18:djag078. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. LIM H, Byun J, Ripley RT, Choi J, et al
   Methylation signatures distinguish non small cell lung cancer subtypes and associated with survival in smokers with lung squamous cell carcinoma.
   J Natl Cancer Inst. 2026 Mar 10:djag067. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2026
3. POCOBELLI G, Del Vecchio NJ, Cushing-Haugen K, Kamineni A, et al
   Up-to-date prevalence at recommended ages for discontinuing routine colorectal, cervical and lung cancer screening.
   J Natl Cancer Inst. 2026 Feb 16:djag044. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2026
4. CAO P, De Nijs K, Lee J, Jeon J, et al
   Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study.
   J Natl Cancer Inst. 2026 Jan 23:djag018. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. SAMET JM, Studts JL
   Lung cancer screening: are race- and risk-aware criteria needed?
   J Natl Cancer Inst. 2026 Jan 13:djaf328. doi: 10.1093.
   PubMed    
   
   
   
6. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
   Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
   J Natl Cancer Inst. 2026;118:94-101.
   PubMed     Abstract available
   
   
   
7. WOOSTER M, May M, Agrawal P, Lee J, et al
   The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.
   J Natl Cancer Inst. 2026;118:49-57.
   PubMed     Abstract available
   
   
   
8. BERRINGTON DE GONZALEZ A, Gunter MJ, Schubauer-Berigan MK, Garcia-Closas M, et al
   The multidimensional role of cancer epidemiology in cancer prevention: discovery science and beyond.
   J Natl Cancer Inst. 2026;118:18-25.
   PubMed     Abstract available
   
   
   December 2025
9. MANFUL A, Mercaldo S, Blume JD, Aldrich MC, et al
   Addressing algorithmic bias in lung cancer screening eligibility.
   J Natl Cancer Inst. 2025 Dec 29:djaf298. doi: 10.1093.
   PubMed     Abstract available
   
   
   November 2025
10. RAGER JB, Cao P, Hayward RA, Meza R, et al
    Personalizing lung cancer screening recommendations for heterogenous populations: a microsimulation study.
    J Natl Cancer Inst. 2025 Nov 3:djaf316. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. SELLERS ME, Cronin KA, Lowy DR
    Stat Bite: Urban and Rural Lung Cancer Mortality Trends in the United States.
    J Natl Cancer Inst. 2025;117:2417-2418.
    PubMed    
    
    
    
12. NUCCIO A, Salomone F, Servetto A, Ricciuti B, et al
    Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.
    J Natl Cancer Inst. 2025;117:2388-2393.
    PubMed     Abstract available
    
    
    October 2025
13. KHOR S, Carlson JJ, Basu A, Bansal A, et al
    The association between new cancer therapy innovations and financial toxicity.
    J Natl Cancer Inst. 2025;117:2021-2028.
    PubMed     Abstract available
    
    
    September 2025
14. HAAS JS, Todd KW, Mclerran D, Tiro JA, et al
    Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
    J Natl Cancer Inst. 2025 Sep 10:djaf248. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. FAN Y, Jin R, Monterroza L, Liu X, et al
    Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.
    J Natl Cancer Inst. 2025;117:1858-1867.
    PubMed     Abstract available
    
    
    August 2025
16. PATON EL, Cetnar JP, Freeman-Daily J, Feldman J, et al
    Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated adverse events.
    J Natl Cancer Inst. 2025;117:1664-1672.
    PubMed     Abstract available
    
    
    
17. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
    Early identification of weight loss trajectories in advanced cancer and associations with survival.
    J Natl Cancer Inst. 2025;117:1729-1732.
    PubMed     Abstract available
    
    
    July 2025
18. 
    Correction to: Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin.
    J Natl Cancer Inst. 2025 Jul 28:djaf184. doi: 10.1093.
    PubMed    
    
    
    
19. ABURAKI R, Fujiwara Y, Haketa S, Horita N, et al
    Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
    J Natl Cancer Inst. 2025 Jul 24:djaf190. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. LAVERY JA, Chen Y, Panageas KS, Wang Y, et al
    Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.
    J Natl Cancer Inst. 2025 Jul 10:djaf176. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. XIA L, Pu Q, Kang R, Mei J, et al
    Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study).
    J Natl Cancer Inst. 2025;117:1474-1484.
    PubMed     Abstract available
    
    
    
22. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    PubMed     Abstract available
    
    
    June 2025
23. ZHANG J, Wang S, Li T, Liu X, et al
    RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis.
    J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093.
    PubMed    
    
    
    May 2025
24. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed     Abstract available
    
    
    March 2025
25. ZHOU P, Cui J, Sun R, Liu X, et al
    RE: Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025 Mar 27:djaf081. doi: 10.1093.
    PubMed    
    
    
    
26. MILDER CM, Cahoon EK, Schonfeld SJ, Preston DL, et al
    Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiologic technologists.
    J Natl Cancer Inst. 2025 Mar 20:djaf064. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. NOGUEIRA LM, Yabroff KR, Yates E, Shultz JM, et al
    Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery.
    J Natl Cancer Inst. 2025 Mar 11:djaf040. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
28. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available
    
    
    January 2025
29. KANAYA N, Seddiq W, Chen KS, Kajiwara Y, et al
    Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis.
    J Natl Cancer Inst. 2025 Jan 22:djaf006. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    PubMed     Abstract available
    
    
    
31. TUMINELLO S, Turner WM, Untalan M, Ivic-Pavlicic T, et al
    Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025;117:112-119.
    PubMed     Abstract available
    
    
    November 2024
32. GOMEZ SL, DeRouen M, Chen MS Jr, Wakelee H, et al
    Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.
    J Natl Cancer Inst. 2024 Nov 20:djae299. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. SMITH RJ JR, Zollo R, Kalvapudi S, Vedire Y, et al
    Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.
    J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
34. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available
    
    
    
35. CHU X, Tian W, Ning J, Zhou R, et al
    Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis.
    J Natl Cancer Inst. 2024;116:1571-1586.
    PubMed     Abstract available
    
    
    September 2024
36. PROSPER AE, Lin Y, Aberle DR
    Lung cancer screening with low-dose computed tomography-where do we go from here?
    J Natl Cancer Inst. 2024 Sep 16:djae197. doi: 10.1093.
    PubMed    
    
    
    August 2024
37. LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al
    Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    June 2024
39. ZHANG EY, Cheung LC, Katki HA, Graubard BI, et al
    The risk and benefit profiles of US eligible lung cancer screening attendees vs. non-attendees.
    J Natl Cancer Inst. 2024 Jun 27:djae148. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. HENDERSON LM, Durham DD, Gruden J, Pritchard M, et al
    Comparing characteristics of individuals screened for lung cancer with 2021 versus 2013 USPSTF recommendations.
    J Natl Cancer Inst. 2024 Jun 24:djae141. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. WU X, Zhang B
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 8:djae130. doi: 10.1093.
    PubMed    
    
    
    
42. TAKI T, Ishii G
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 7:djae131. doi: 10.1093.
    PubMed    
    
    
    
43. SCHUZ J, Kovalevskiy E, Olsson A, Moissonnier M, et al
    Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study).
    J Natl Cancer Inst. 2024;116:866-875.
    PubMed     Abstract available
    
    
    
44. UPRETY D, Seaton R, Hadid T, Mamdani H, et al
    Racial and socioeconomic disparities in survival among patients with metastatic Non-Small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
45. FUCITO LM, Palmer AM, Baldassarri SR
    A new perspective on mitigating lung cancer risks through smoking cessation and reduction.
    J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093.
    PubMed    
    
    
    
46. NAGASAKI Y, Taki T, Nomura K, Tane K, et al
    Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
47. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    PubMed     Abstract available
    
    
    
48. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
49. GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al
    Changes in smoking use and subsequent lung cancer risk in the ATBC study.
    J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
50. SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al
    Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the U.S., 1991-2018.
    J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al
    Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
    J Natl Cancer Inst. 2023;115:1515-1525.
    PubMed     Abstract available
    
    
    
52. ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al
    Global epidemiologic patterns of oropharyngeal cancer incidence trends.
    J Natl Cancer Inst. 2023;115:1544-1554.
    PubMed     Abstract available
    
    
    November 2023
53. LEHRER S, Rheinstein PH
    Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
    J Natl Cancer Inst. 2023;115:1427-1428.
    PubMed    
    
    
    
54. LU K, Wang HC, Tu YC, Chang CC, et al
    Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
    J Natl Cancer Inst. 2023;115:1383-1391.
    PubMed     Abstract available
    
    
    
55. EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al
    Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    J Natl Cancer Inst. 2023;115:1404-1419.
    PubMed     Abstract available
    
    
    September 2023
56. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
    Circulating proteome for pulmonary nodule malignancy.
    J Natl Cancer Inst. 2023;115:1060-1070.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum